Medicine Description Certican 0.25 mg
Certican 0.25 mg tablets is a medication that functions as an immunosuppressant by inhibiting the mammalian target of rapamycin (mTOR), a crucial kinase involved in cell growth, proliferation, and survival. Everolimus blocks the signaling pathways that promote T-cell activation and proliferation, thereby reducing the immune response that could lead to organ rejection. By impeding these pathways, Certican effectively lowers the likelihood of transplant rejection while allowing for controlled immune regulation. Moreover, in the context of cancer, this inhibition of mTOR disrupts the growth of certain tumor cells, making it beneficial in treating specific malignancies.
Indications and Uses of Certican 0.25 mg tablets
- Prevention of organ transplant rejection in kidney and liver transplants
- Management of advanced renal cell carcinoma
- Treatment of neuroendocrine tumors
Side Effects of Certican 0.25 mg tablets
- Increased risk of infections
- Gastrointestinal disturbances such as nausea and diarrhea
- Potential for kidney dysfunction
- Elevated blood lipid levels
- Skin rashes and other dermatological reactions
Storage and Handling
Store Certican tablets at room temperature, away from moisture and heat. Keep the medication in its original container and ensure it is out of reach of children.
Patient Advice and Precautions
Before starting treatment with Certican, inform your healthcare provider about any pre-existing health conditions or allergies. Regular monitoring of kidney function and blood lipid levels is advisable during therapy. Patients should avoid live vaccines while on this medication due to the increased risk of infections. It is important to adhere to follow-up appointments for monitoring and to report any unusual symptoms promptly.